We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Study Shows Importance of mTORC1 and p21 Signaling in Head and Neck Carcinomas

By LabMedica International staff writers
Posted on 15 Feb 2016
A team of Spanish cancer researchers has found that over-activation of the mTORC1/4E-BP1/p21 molecular pathway is a frequent and clinically relevant alteration in head and neck squamous cell carcinomas (HNSCC).

Investigators at Centro Nacional de Investigaciones Oncologicas (Madrid, Spain) and the Central University Hospital of Asturias (Spain) analyzed more than 270 biopsies of patients with head and neck cancers and found that about half of them showed high levels of p21 protein as well as mTOR activation.

The p21 (cyclin-dependent kinase inhibitor 1) protein is a potent cyclin-dependent kinase inhibitor, which binds to and inhibits the activity of cyclin-CDK2, -CDK1, and -CDK4/6 complexes, and thus functions as a regulator of cell cycle progression at G1 and S phase. More...
In addition to growth arrest, p21 can mediate cellular senescence. The expression of the CDKN1A gene, which encodes p21, is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli.

Mammalian target of rapamycin (mTOR) is a master regulator of protein synthesis that under ordinary conditions induces cells to grow and divide. However, in cancer cells the mTOR pathway does not function correctly and signals tumor cells to grow, divide, undergo metastasis, and invade new, healthy tissues. Functionally, mTOR is the catalytic subunit of two structurally distinct complexes: mTORC1 and mTORC2. Both complexes localize to different subcellular compartments, thus affecting their activation and function. MTORC1 is composed of the proteins mTOR, regulatory-associated protein of mTOR (Raptor), mammalian lethal with SEC13 protein 8 (MLST8), and the non-core components PRAS40 and DEPTOR. This complex functions as a nutrient/energy/redox sensor and controls protein synthesis. The activity of mTORC1 is stimulated by insulin, growth factors, serum, phosphatidic acid, amino acids (particularly leucine), and oxidative stress.

In the current study, the investigators described a new mechanism of regulation of p21 by the mTORC1/4E-BP1 pathway. The 4E-BP1 gene encodes eukaryotic translation initiation factor 4E-binding protein 1, which is a member of a family of translation repressor proteins. The protein directly interacts with eukaryotic translation initiation factor 4E (eIF4E), which is a limiting component of the multi-subunit complex that recruits 40S ribosomal subunits to the 5' end of mRNAs. Interaction of this protein with eIF4E inhibits complex assembly and represses translation. This protein is phosphorylated in response to various signals including UV irradiation and insulin signaling, resulting in its dissociation from eIF4E and activation of cap-dependent mRNA translation.

The current study showed that non-phosphorylated 4E-BP1 interacted with p21 and induced its degradation. Accordingly, hyper-activation of mTORC1 resulted in phosphorylation of 4E-BP1 and stabilization of p21. In HNSCC, p21 levels strongly correlated with mTORC1 activity but not with p53 status. Clinical data indicated that HNSCC patients with p21 and phospho-S6-double-positive tumors presented a better disease-specific survival.

"One problem is the stratification of patients, which in many cases is limited to a clinical classification, not a molecular one," said contributing authors Dr. Susana Llanos and Dr. Juana M. García-Pedrero, researchers at Centro Nacional de Investigaciones Oncologicas and the Central University Hospital of Asturias, respectively.

The study was published in the February 2, 2016, online edition of the journal Nature Communications.

Related Links:

Centro Nacional de Investigaciones Oncologicas
Central University Hospital of Asturias 



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.